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Abstract—Advances in medical technology rely heavily on 
the collection and analysis of measured data to facilitate 
patient diagnosis and business decisions.  The healthcare 
industry, particularly pharmaceuticals and diagnostic 
processes, has an ongoing need to improve item tracking and 
data collection to improve the quality of care while reducing 
cost.  The remote, non-invasive characteristics of RFID can 
facilitate the information needs of healthcare without 
imposing additional burden onto the patient or staff.  
Properly deployed RFID enabled devices can provide 
convenient and accurate data for disease diagnosis, 
evaluation of prescription non-compliance and identification 
of medication dosage errors. This paper describes an all-
encompassing RFID tracking system that begins with 
compliance documentation from the drug manufacturer 
through confirmation of patient compliance by capsule 
extraction from the bottle, into a pill case and ultimately 
ingested or inserted into the body.  This RFID system can 
provide data for decision-making and facilitate compliance 
with FDA proposed e-pedigree requirements.  This 
transcript provides an introduction to healthcare trends in 
order to motivate the need for a biocompatible RFID system.  
An approach to research as well as an in vitro tabletop test 
 method is presented in light of pending research.  The 
overall goal of the pending research is to develop 
biocompatible RFID tag components for use with systems 
beginning with the manufacturer and continuing through 
distribution to the point of interest within the patient’s body. 
Keywords— RFID; e-pedigree; pharmaceuticals; tracking 
1. Introduction 
The chipped pills concept was a very important 
technology and now feasible because of clinical trial 
results. Previous research by the authors theorized on how 
this would impact the medical/pharma supply chain and 
enable the e-pedigree initiatives. Technological advances 
such as micro electromechanical systems (MEMS), digital 
communications, and GPS/RFID applications coincide 
with the induction of electronic prescriptions, targeted 
drug delivery, nanoparticles, and biocompatible 
biosensors to create a new standard for medical service 
and new paradigm for personalized medical care for the 
patient.  This paradigm shift to improve the quality of 
healthcare is toward more intimate patient-provider 
relationships and better medication management.  The 
demand for improved communication between patients, 
doctors, medical insurance providers, and pharmacists 
now includes pharmaceutical manufacturers since the 
requirement for electronic-pedigree (e-pedigree), 
documentation of pharmaceuticals was instituted by the 
FDA (Food and Drug Administration). 
Chronic and communicable diseases negatively affect 
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patient quality of life and increase the financial impacts of 
continued patient care.  Future improvements in treatment 
methods and healthcare management rely on the collection 
of reliable data for decision-making.  This transcript 
outlines a comprehensive view of pharmaceutical tracking 
and monitoring from the pharmaceutical manufacturer to 
ingestion by the patient.  Preventable medication 
administration errors and patient non-compliance impose 
additional burdens to patients.  Development of devices 
and systems for improved, convenient data collection and 
automated positive identification of medication and 
patient status can eliminate some of this burden. 
Biocompatible radio frequency identification (RFID) 
tracking and monitoring systems can be used safely to 
facilitate the non-invasive collection of information to 
improve the quality of care to the patient.  Integration of 
RFID technology for pharmaceutical tracking and tracing 
immediately provides increased potential to optimize 
product delivery and logistics, ensure product safety, 
monitor product administration, enhance patient 
compliance, and ultimately improve drug effectiveness.   
Such a system, capable of tracking patients, all of their 
medications, and their prescription compliance would also 
eliminate errors in medication administration, improper 
dosages, and adverse reactions to pharmaceuticals, which 
disproportionately affect the aging population.  A wireless 
system capable of measuring and reporting physiologic 
data will not only facilitate current monitoring systems 
and data collection but may also create real-time methods 
to assess therapy and control chronic illnesses and 
communicable diseases.  The benefits of a non-invasive, 
biocompatible RFID system and its potential for collecting 
and transmitting large amounts of data , extend beyond the 
clinic and into the daily activities of the patient.  Such a 
system is a potentially invaluable tool to support the 
medical industry in its pursuits. 
2. Background 
2.1 Impact of Chronic Diseases 
Most chronic diseases do not result in sudden death.  
Rather, they are likely to cause people to become 
progressively ill and debilitated.  This is especially true if 
their illness is not managed correctly.” Chronic non-
communicable diseases include cardiovascular diseases 
(heart disease and stroke), cancers, chronic respiratory 
conditions and type II diabetes and account for 60% of the 
deaths worldwide.  These chronic diseases affect 
everyone., and are a significant cause of premature 
disability and death as indicated by the DALY (disability 
adjusted-life years) statistics in epidemiological studies .   
2.2 Impact of Medical Errors and Patient 
Non-Compliance 
Errors in medication administration, improper dosages, 
and adverse drug affects have been reported to occur at a 
rate of over 1.5 million annually.  This phenomenon 
disproportionately affects elderly and chronically ill 
patients and can have a huge impact on the spread of 
highly commutable diseases.  Elderly patients have higher 
risk of miscommunication with their doctors, and often 
have multiple doctors treating a variety of age-related 
illnesses.  Annual costs associated with reducing 
medication errors and monitoring, and confirming proper 
drug administration of patient medication is over $1 
Billion .  There is a critical need to address these health 
issues using the technological resources available.   An 
RFID biosensor that can confirm the ingestion of 
medications by people who are being treated for either 
communicable or chronic diseases and transmit that 
information back to the provider can be invaluable.   
2.3 Data Collection needs for Healthcare 
Systems 
The implementation of convenient and non invasive 
methods for patient care and data collection will provide 
the most intervention on which to make informed policy 
and healthcare decisions.  The entire medical community 
can utilize the data collected in this way to improve the 
care provided to the patient from the context of a business 
plan to providing efficient and accurate diagnosis of 
chronic conditions and reliable methods improve the 
quality of life for those affected.  RFID systems are an 
effective means to meet these objectives. 
2.4 RFID Technology 
Radio Frequency Identification or RFID is a unique 
identifier, similar to a bar code, generated by data-
associated radio signals.  The advantages of RFID over the 
bar code and other identification systems include the 
elimination of a required unobstructed visual line of sight 
and a significantly larger capacity to collect and 
communicate information.  RFID systems consist of a host 
computer, an interrogator or reader,, a media (air) 
interface, and a transponder or tag. RFID tags can be 
passive or active. Passive tags utilize the energy of a 
reflected signal through inductive coupling to transmit 
information to the initiating interrogator; active tags are 
powered by batteries and can support larger memory chips 
for longer transmission distance and submit more 
information.  Well-planned design and utilization of RFID 
systems can fulfil RFID mandates and provide value-
added data for business and healthcare organizations. 




Figure 1.Progressive Research Path 
The real-time experience between service providers and 
potential customers have potential for data collection and 
tracking of assets, patients, and patient care in the health 
care arena and improve efficiency in all aspects of the 
healthcare supply chain. 
2.5 FCC Regulations and Standards for RFID 
applications  
Part 15 of the Federal Communications Commission 
(FCC) regulation for low-powered devices applies to 
RFID technologies.  Passive RFID systems are relatively 
low power; therefore, it is unlikely these limits will be 
reached in most circumstances [8].  It is important to note 
that a study initiated by the Centre for Devices and 
Radiological Health (CDRH) and the FDA found no 
adverse effects of radio waves in the body or on drug 
stability and are of no risk to product quality. 
2.6 Biocompatibility 
The biocompatibility and biostability are of highest 
priority in developing a ingestible RFID- tagged 
pharmaceutical device and reader.   Similar devices have 
successfully been implemented, such as implantable RFID 
chips utilized for the tracking of livestock and household 
pets.  Development of an RFID tag has challenges 
inherently unique to the intended functional environment.  
These challenges include issues of safety, toxicity, 
carcinogenicity, and physiologic responses.  
Manufacturers of medical devices must demonstrate 
device biocompatibility to ensure patient safety, proper 
device function, and to fulfill regulatory (FDA) 
requirements.  The ISO 10993 standard provides 
principles for evaluation of devices, including in vitro and 
in vivo scenarios that can be applied to meet regulatory 
requirements. 
For the development of the proposed RFID 
tag/biosensor, lubricity, blood compatibility, drug 
delivery, and anti-microbial surface properties are 
important considerations to reduce the chance of adverse 
reactions. 
2.7 Research Objectives 
How can the breakthrough in chipped pills extend to the 
usage of RFID enabled chipped pills and devices.  We 
hypothesize that with these clinical trails that they can be 
expanded to include RFID micro chips described in the 
previous research.  The test protocols and the political will 
for testing these innovations have come of age. We will 
describe how testing the RFIID technology can impact the 
medical errors associated at different points in the pharma 
supply chain. The goal of this research is to develop a 
multi-purposed, ingestible RFID tag and biosensor to 
facilitate tracking and data collection at tablet level from 
the manufacturing lot, through the pharmacy, to 
consumption by the patient.  This will involve the 
development and validation of a manufacturable, 
biocompatible RFID tag/sensor device for pills. This 
component of the system must be miniaturized to a scale 
easily incorporated into the pharmaceutical target and 
must maintain electronic performance while posing no or 
minimal risks to the patient.  Consideration will be given 
to electronic effects upon existing diagnostic techniques, 
such as magnetic resonance imaging (MRI.)  To reach the 
research goal we seek to accomplish two objectives. 
2.7.1 Objective for Industrial Applications 
Develop a biocompatible, micro-RFID tag/biosensor, 
incorporated into a pharmaceutical matrix, to create a 
system that will improve the traceability, e-pedigree and 
control of prescription medication. 
2.7.2 Objective for in Vivo Applications 
Develop an ingestible, biocompatible RFID tagged 
pharmaceutical and biosensor to provide confirmation of 
ingestion by the patient and to improve the non-invasive 
collection of data and monitor internal body conditions, 
such as pH, temperature, and perhaps one day determine 
the amount of drug released into the patient’s system.   
This paper describes a comprehensive view of 
pharmaceutical tracking and monitoring from the 
pharmaceutical manufacturer to ingestion by the patient.  
In addition, the FDA e-pedigree requirements and current 
research uses of RFID in medical practice are described 
and are part of the rationale for our research objectives.   
2.8 History of ePedigree 
The USA Congress passed the PDMA (Prescription Drug 
Marketing Act) in 1987, which required a statement 




known pedigree for selling a drug. The pedigree was 
supposed to have information about sales including date of 
transaction, names, and address and more. However, even 
after FDA published final rules to implement the pedigree 
in 1999, it was not in effect until 2006 due to strong 
opposition to pedigree law. One of the reasons the FDA 
delayed the effective date of PDMA was ePedigree. 
Industry promised that it would implement an electronic 
track and trace system by 2007, which obviously could 
meet pedigree requirements. However, since it was also 
obvious that industry could not do that by 2007, FDA 
published a notice mentioning no more delay of PDMA in 
June 2006. It published also PDMA CPG (Compliance 
Policy Guide) in December 2006 (FDA 2006). Each state 
government also passed its own laws against counterfeit 
and diverted drugs. Allowing each individual state to 
develop its own approach to the counterfeit and diverted 
drug problem has brought some issues related to 
standards. For instance, if 50 states in the US have their 
own regulations, and they are not on the standard format 
with pedigree law, it might give overwhelming burdens to 
small and mid-sized companies by increasing cost and 
operation difficulties (Gregory Conko 2013). Finally, the 
US president, Barack Obama signed Drug Quality and 
Security Act (DQSA) in November 2013. It required FDA 
to provide implementation guidance within 12 months and 
develop a national track and trace system to secure the 
pharmaceutical supply chain. It also required that all drug 
packages carry a serial number within 4 years (Phil Taylor 
2013).  
2.8 Pharmaceutical Regulations (FDA) and e-
pedigree 
The FDA regulates the commerce of pharmaceuticals and 
medical devices.  The Prescription Drug marketing Act of 
1987 (PDMA) and the Prescription Drug Amendments of 
1992 (PDA) address the regulations enforceable by the 
FDA.  21 CFR Parts 203 & 205 specify that 
pharmaceutical wholesalers provide a statement, referred 
to as the pedigree, prior to each distribution of a product.  
The pedigree requirements include information about the 
wholesaler and the name, dosage, and strength of the drug, 
or the national drug code (NDC) number.  Electronic 
pedigrees (e-pedigree) have been proposed to meet the 
requirements of 21 CFR §203.  In the addendum to the 
FDA’s Guidance for Industry, it is strongly recommended 
that prior transactions and lot control also be included in 
the pedigree or e-pedigree.   
RFID technologies have been discussed as a viable 
method to meet the pharmaceutical e-pedigree mandate.  
One force driving pedigrees from paper to electronic 
forms is concern about counterfeit drugs and forgery of 
paper pedigrees.  The FDA’s Counterfeit Drugs Task 
Force stated in a 2004 report, “FDA has concluded that 
these-pedigree approach is a much more reliable direction 
for assuring the legitimacy of a drug than paper record-
keeping requirements”.  RFID technologies can provide a 
platform to meet FDA requirements and are commonly 
suggested for both e-pedigree requirements and protection 
against counterfeiting. 
2.8.1 Basic Concepts of ePedigree 
One of two main concepts of ePedigree is the 
implementation of traceability and visibility for the 
pharmaceutical products. Based on the federal pedigree 
law, each product unit must have a globally unique 
serialized number and ePedigree system can track and 
trace the unit level of any product by inquiring its 
serialized number (Phil Taylor 2013). This unit level 
serialization enables not only wholesalers but also end 
users to authenticate the products that they buy, and it 
could support better secured PSC against counterfeit and 
diverted drugs. The other main concept of ePedigree is the 
authentication process. Based on pedigree law, it generally 
requires wholesalers or other participants pass the 
documented pedigree, which has product, trading partners’ 
information, and their signature for authentication to the 
recipients. However, when it comes to ePedigree, the 
authentication algorithm could be different based on what 
standard the companies have integrated into their 
ePedigree systems. For example, Drug Pedigree 
Messaging Standard (DPMS) ratified by Global Standard 
One (GS1, http://www.gs1.org) in 2007 creates and passes 
pedigrees to the buyers, and the buyers add their 
information to the pedigree and so on. It seems similar to 
the way of document based pedigree systems but the only 
difference is the electronic document type and digital 
signatures. Since some states do require only paper based 
pedigree currently, ePedigree needs to support a document 
based pedigree feature by allowing the attachment of files 
and manual authentication (EPCglobal 2007). However, 
Electronic Product Code Information Services (EPCIS) 
does the authentication in different ways. Since Drug 
Pedigree Messaging Standard (DPMS) has its weakness in 
several aspects, GS1 proposed EPC network with EPCIS 
for ePedigree. The participant in EPC Network with 
EPCIS can exchange data when they need, which 
improves the data storage space needed with DPMS. The 
trading partners inquire the concerning data from other 
trading partners for ePedigree or traceability information. 
Each participant can have either local EPCIS repository or 
store the data in the centralized databases.  Still there are 
lots of things to be discussed for this standard, e.g., how 
the trading partners pass or share the data to other 
partners, how much data the participant needs to share, 
who initiates ePedigree at first and many more.   
2.9 Current RFID Tracking in Health Care 
2.9.1 Medical Resource Tracking 
Tracking strategies for patients, staff members, 
equipment, and information can be implemented to 
increase the efficiency of health care, as well as facilitate 
better patient outcomes.  Studies have been performed to 
demonstrate the opportunity for resource utilization and 
efficiency increases when equipment location is facilitated 
with an RFID system.  Sangwan proposes an RFID system 
for patients, charts, and equipment location within a multi-
level hospital setting.  This system includes an alert 
system to notify staff members when a tracked item is 




removed from defined boundaries.  Cypack has embedded 
RFID chips into pharmaceutical packaging to track patient 
compliance by monitoring when the package is opened, 
but has not integrated it into the actual medication.  For 
surgical procedures, RFID tags have been tested for 
tracking and tracing surgical sponges in order to eliminate 
errors due to manual counting at the completion of a 
procedure. RFID tracking systems for patients have been 
suggested for containment of infectious disease.  Regular 
monitoring of non-compliant individuals has been 
identified as a method to limit exposure risks. RFID 
systems can allow for this type of monitoring without the 
need for dedicated personnel.  
2.9.2 Medical Record Data Collection 
In addition to performing tasks in a clinical environment, 
staff is required to maintain records of many activities, 
including vital signs and administered medications.  
Accurate documentation of medications and blood 
products are critical for patient safety and mandated by 
regulatory bodies.  The majority of these records are 
written manually or scanned with a bar code.  The 
information contained in the bar code improves the 
identification of the units; however, the amount of 
information contained in the bar code is limited in volume 
and can only contain information available at the time the 
label is printed.   
Sandler discusses a multi-write, passive RFID system to 
track and record unit information from 
manufacture/collection thru administration to the patient.  
Potential benefits of such a system include reduction of 
incidences of incorrect medication or dosages, accurate 
documentation in patient records, and consistent 
information delivery for diagnosis.  An RFID system that 
also incorporates e-pedigree information can reduce the 
response time for diagnosis in emergency situations.  
Creation of host system software to compliment the 
collection and application of the data is limited only by the 
vision of system planners to impact day-to-day operations 
within a clinic.  Large-scale implementation of RFID 
tracking systems in hospitals must overcome the physical 
limitations of current systems.  However, currently 
available system components can be adapted for localized 
installation of systems in a clinical environment. 
2.9.2 Patient Behavior Assessment 
The assessment of a patient’s behavior outside the clinical 
atmosphere has a large potential for accurate diagnosis 
and treatment.  Common methods for data collection 
outside the clinical atmosphere are limited, and are often 
inconvenient and not representative of the true condition 
or behavior of interest.  A non-invasive RFID monitoring 
system has been investigated for the purpose of evaluation 
of a person’s ability to continue independent living.  The 
RFID system is equipped with a sensor to detect motion of 
the individual and tagged items of interest. In this case the 
tagged item of interest is the pharmaceutical.  The data 
provides numerical evidence to evaluate the behavior and 
capability of the individual, thus reducing the labor 
required to perform the observation and evaluate the 
patient’s capacity to continue independent living or to 
comply with medication administration. 
 Epidemiologic evaluation of the effectiveness of 
medication could be determined from an RFID system that 
tracks the behavior of patients with respect to 
administration of prescribed medications outside the 
clinical setting.  The data collected could also be used as 
evidence of the dosage protocol for epidemiological 
studies or as evidence of the effectiveness of treatment 
plans for clinics or public health policies. 
2.9.3 Implantable RFID tags 
RFID tags have been accepted as a means to identify and 
locate both wild and domestic animals.  Recently RFID 
tags were placed into rice sized (2.5 mm x 1.3 mm) glass 
capsules for subcutaneous implantation for the purpose of 
tracking livestock and other animals.  The device is 
biocompatible as a subcutaneous, implantable, tracking 
device.  However, adaption is not directly applicable to 
pharmaceuticals, for example, glass is not well suited for 
oral delivery of medication.   
2.10 Research Question for In Vivo 
Applications 
Can an ingestible, biocompatible RFID tagged 
pharmaceutical and biosensor be designed and 
implemented to improve the non-invasive collection of 
data and monitor internal body conditions, such as pH, 
temperature, or mass of drug released into the GI tract?   
Diagnosis of patient status requires accurate information 
about the patient’s physiologic state.  Health care 
providers generally prefer less invasive techniques when 
the function is of better or equal benefit to the patient.  
Consequently, new techniques and technological 
innovation tools for healthcare continue to immerge for 
corrective and diagnostic procedures.   
2.10.3 Current Non-Invasive Measurement 
Techniques in Health Care 
The acidic environment of the GI tract poses challenges to 
designers to develop devices that can survive in the harsh 
environment.  Ativanichayaphong has investigated an 
implantable RFID tag for the task of diagnosing 
esophageal reflux.  This device is viable for approximately 
two weeks in the gastrointestinal tract environment, and 
has a footprint of 40 mm2.  A reduction in the amplitude 
of the signal transmitted from the tag to the interrogator 
indicated the presence of acid.   
A wireless endoscopy system known as the PillCam 
SB® used for gastrointestinal disease diagnosis has 
received FDA approval.  This device is comprised of a 
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silicon chip camera, lens, LED, silver oxide battery and 
UHF band radio telemetry transmitter encapsulated in a 
disposable plastic capsule (11 x 26 mm.) It passes through 
the GI tract within 72 hours while transmitting color 
images.  Another GI tract diagnostic tool, known as the 
“Smart Pill”, has been developed.  This 13 x 26 mm 
ingestible pill utilizes MEMS sensors to measure pH, 
pressure and transit time within the GI tract.   
3. Methodology 
Realization of a functional biocompatible RFID system 
can be achieved with development of a biocompatible 
RFID tagged pharmaceutical and biosensor utilizing 
existing technological developments from MEMS, 
antenna design, biomaterials, material selection 
techniques, interdisciplinary engineering (industrial, 
electrical, biomedical, manufacturing), biochemistry, and 
medical research.  However any RFID system designed 
must consist of individual components (tag, transmission 
medium, interrogator, and host system) that perform 
predictably and reliably in the environment of intended 
use.   
Transmission strength and ranges, reproducibility and 
reliability, performance in specified environments, 
measurement capabilities, and durability in vivo will be 
considered in the experimental designs.  Biocompatibility 
testing will be performed as necessary utilizing ISO 10993 
as a guide. Successful tabletop testing of components and 
systems preclude any in vivo testing in humans or other 
living organism.  Figure 1 demonstrates a conceptualized 
progression of the biocompatible RFID tagged 
pharmaceutical and biosensor for research and 
development.  Advancement of the tag’s capabilities will 
build upon the technology developed during earlier phases 
of research.  The advantage of this approach is relatively 
quick development of tracking systems that can be utilized 
for anti-counterfeit, FDA e-pedigree, and collection 
business metrics at the completion of the first phase: the 
biocompatible RFID tag.  Optimization and acceptance of 
this relatively simple system component will improve the 
technology base for development of a pass-through RFID 
tagged pharmaceutical and biosensor.  Implantation of 
RFID tags in humans is not widely accepted; evidence of 
the value and biocompatibility of an RFID-tagged 
pharmaceutical and biosensor in the GI tract will help 
answer concerns about the effects of RFID technology in 
close proximity to tissues in living beings.  The ultimate 
goal is to develop an RFID-tagged pharmaceutical and 
biosensor that can safely pass through the GI tract and 
then be safely eliminated from the body.  Conceptualized 
biocompatible RFID systems are pictured in Figure 2. 
 
Figure 2.RFID ePedigree Flow Chart 
Retail and warehouse RFID systems utilize an air interface 
as the transmission medium between the interrogator and 
tag.  The electrochemical nature and high water content of 
the human body pose challenges to RFID transmissions.  
Previous research has been conducted on the interaction of 
RFID communication in the presence of humans.  
Tabletop simulation models have been created for 
compliance testing of mobile communication devices , 
evaluation of antenna designs in close proximity to the 
human body, and evaluation of RFID sensors in the acidic 
GI tract environment.   
 
Figure 3.Biocompatible RFID Systems Vad (Ventricular 
Assist Device) Image Reprinted with Permission from 
Thoratec Corporation 
4. Results 
4.1 Proposed Medical Device 
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Flowchart Diagram and discussion of supply chain 
including e-pedigree integration. The BRTP can be 
integrated into the medical supply chain.  We envision that 
the manufacturer will program the BRT into the 
pharmaceutical, pills in our example.  These pills then can 
be tracked from manufacturer, through the supply chain 
from the transportation system, to storage, to the supplier 
and finally to the consumer until ingestion.  Furthermore 
this device will facilitate and automate pharmacy 
inventory reorder. The initial devices and scenarios we 
envision are described in below. 
4.2 Device Components 
4.2.1 Biocompatible RFID tagged Pharmaceutical 
(BRTP) 
This BRTP, the embedded pill, will be able to contain 
information which includes the lot and manufacturer that 
it was created from to the retailer that sold the bottle to the 
customer.  The BRTP is envisioned to use interoperable 
RFID standard transmission frequencies so that it can be 
scanned throughout the supply chain.  It will follow e-
pedigree standards but will also contain a temperature 
sensor to monitor temperature during shipping and 
storage.  Feedback will confirm delivery to the pharmacy 
or other retail establishment.   It will also allow the 
supplier and the retailer to monitor inventory thereby able 
to replenish the stock when a certain set minimum is 
reached.    Physicians and pharmacists will be able 
monitor patient compliance with administration of the 
drug as directed and patients will be able to manage their 
medications with confidence.   
4.2.2 BRTP Bottle/Cap Reader 
This device shown in Figure 4 contains an interrogator 
that scans and records the number of RFID enabled pills 
within the bottle.  The device can transmit this information 
by to a simple computer with downloadable software or 
Bluetooth.  
 
Figure 4.RFID Tagged Bottle/Smart Cap 
4.2.3 BRTP Wand Reader 
The BRTP wand will be used to scan the abdominal wall 
to confirm that a specific pill was ingested as depicted in 
Figure 5.  It is also envisioned that the design of the wand 
allows for in vivo detection for confirmation within 72 
hours.   Interrogation may also be performed during 
outpatient or surgical procedures. 
4.2.4 Real Case Scenario 
Consider a scenario in which a patient is prescribed 
medicine and must take the two pills 3 times a day.  The 
patient does not recall if they took the medicine.  The 
patient then proceeds to count the pills in the bottle and 
discovers that two pills are missing.  They have confirmed 
that two pills were taken from the bottle, but are still not 
sure that they ingested the pills.  The devices described 
below will allow that patient to confirm both.  The BRTP 
bottle reader confirms that pills were taken out of the 
bottle, without the timely inaccurate process of counting 
pills.  The BRT wand confirms that the pills were ingested 
within 24 hours.  Of course this situation does not have to 
be limited to routinely prescribed medicine but there is 
great incentive for patients, physicians and drug 
manufactures utilize BRTP technology for medicines 
where compliance is critical to the outcome.  For example, 
in infectious diseases such as Tuberculosis, this research 
could verify that pills were taken and assist in preventing 
additional outbreaks or the development of drug resistant 
strains of the bacteria. 
 
Figure 5.Wand or Interrogator 
 




Table 1.Pharmaceutical Supply Chain challenges and their RFID enabled Solutions 
 
Issues and Challenges 
Chipped Pill 




• Crisis Management in epidemic 
break-outs 
• Global demand for medicines 
overshoots the demand suddenly.  
• Product withdrawal during sales 
due to side-effects and expiry 
• Tracking specific 
medicine  
• More relevant and 
complete data 
 
• Readability in 
challenging 
environments 
• Read and write speeds 
• More relevant and 
complete data 
Manufacturing 
• Reluctant Govt. bodies to approve 
any Outdated Manufacturing Sites 
changes fearing  Cross trading 
across Parallel Trade product 
quality 
• No track  
• Black market transactions in 
developing nations the borders of 
drugs coming in & going out of 
the country 
• Adaptable but tedious 
• Transmits data for 
tracking 




• Security features 
• Portability to multiple 
device form factors 
• Ready to go readers 
• Locating technology 
• Data integration 
Warehouse 
• Controlling wide supply chain 
with huge Stock 
•  Complex Network Design 
Keeping Units   
• Reducing finished goods is 
becomes very difficult 
• Training difficult & education 
cost to the stakeholders is high 
• Integration of domestic and 
international businesses. 
• Sales  
• Fast inventory 
• Location guided 
solution 
• System integration 
• Must have transmission 
device 
• Limited data 
• Interoperability 
• Industry oriented 
solutions 
• Cloud based platforms 
• Cross functional 
collaboration 
Hospital 
• Ethical requirement of Little 
Incentive for Reducing Inventory  
Out of stock situations are 
unacceptable 
•  Medicines & patent lifespan is  
Exceptionally long cycle times 
and lots of low  High price of 
drugs 
• Counterfeit Drugs 
•  Security 
• Inventory  Easy to fake 
prescription drug labeling 
worldwide 
• Location of medicine 




• Ecosystem of partners 
and solutions 
• Performance of devices 
• Pricing and total  
• cost of ownership 
•  
Pharmaceutical 
• Degradation of Managing 
perishable products 
• Managing Pharmaceuticals the 
medicines as they move along the 
supply chain which results in 
allowing substandard products to 
be dispensed to the patients   
• Typically more focus is given on 
Maintaining temperature control 
Manufacturers can’t have control 
once Pharmaceuticals are 
Shipping of expiry products 
• Docked to wholesalers 
• Ingestible 
• No illegal sharing of 
pills 
• High cost 




• Interoperable trading 
partner solution 









The ability to use RFID methods to track logistical 
movements of pharmaceuticals from the manufacturer to 
the pharmacy is possible with current RFID technology 
used for retail applications.  RFID tracking of 
pharmaceuticals at the pill level through its entire life 
cycle from the manufacturer to ingestion by the designated 
patient is achievable.  The challenge remains to develop 
and incorporate this technology into the medication in a 
manner that is suitable for consumption. Pharmaceutical e-
pedigree requirements can be fulfilled with minimal labor 
with the incorporation of an RFID tracking system at the 
pill level. Community health programs and 
epidemiological studies can utilize data collected by a pill 
level RFID tagged pharmaceutical and biosensor to 
support policies and study results.  Deployment RFID 
systems with pill level tags in a clinical environment can 
assist the staff with monitoring inventory, positively 
identifying medication administered, and confirming the 
drug was administered as directed.  Potential drug 
interactions or adverse side effects can be identified 
quickly to reduce the burden on the patient.   
 Outside the clinical environment, management of 
medications can be a challenge for patients.  Monitoring 
and communication with the patient can improve patient 
compliance, especially in such cases when it is necessary 
for healthcare professionals to oversee the administration 
of each dose, a common practice in the treatment of 
tuberculosis today.   
Devices that can measure physiologic conditions real-
time have the greatest potential to minimize the impacts of 
chronic and communicable diseases.  Advancing the reach 
of non-invasive RFID data collection to the in vivo point 
of interest requires development of unique ingestible 
biosensors.   
The information provided by these biocompatible RFID 
systems can enable the healthcare provider to making real-
time adjustments to suit the individual patient needs and 
improve the business dynamics with stake holders, 
manufacturers, pharmacists, doctors, patients, insurance 
carriers, researchers and patients.  Biocompatible RFID 
tag deployment via the GI tract can be more convenient 
for the medical staff and less painful to the patient than 
allowed by current measurement techniques.  This 
convenience will increase patient compliance for repeated 
testing or long term monitoring, and as a result, improve 
the quality of life for the patient.  Ultimately the patient is 
the beneficiary of improved healthcare and overall health. 
This biocompatible RFID system is easily adaptable to 
address the needs of the elderly and those taking 
medication daily or for extended periods of time.  
Incorporation of the BRT onto a pill box can reduce 
medication errors and help to ensure that medication is 
administered as prescribed.  Future goals are to provide a 
RFID enabled platform for continuous tracking of the 
pharmaceutical to measure therapeutic impact.  We 
theorized potential for targeted, controlled, RFID enabled 
drug delivery systems will one day enable us to monitor 
the release of drugs through the gastrointestinal tract.  This 
further enhances the medical capability of measuring 
bioavailability of drugs that are absorbed into the 
bloodstream to determine the efficacy. 
6. Conclusion 
It is an exciting opportunity to reduce medical errors 
and costs in the pharma supply chain.  With the new 
breakthroughs in research including clinical trials, and the 
implementation of the e-pedigree the benefits of RFID 
chipped pills can be recognized.  The use of the RFID 
standard to enhance the capabilities and reduction of cost 
using the smart pills has come of age.  If you are 
interested in further information on our studies feel free to 
contact the researchers. Outside the clinical environment, 
management of medications can be a challenge for 
patients.  Monitoring and communication with the patient 
can improve patient compliance, especially in such cases 
when it is necessary for healthcare professionals to 
oversee the administration of each dose, a common 
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